Published in Vaccine Weekly, January 18th, 2006
"Immunotherapy is a novel potential treatment for nicotine addiction. The aim of [our] study was to assess the safety and immunogenicity of a nicotine conjugate vaccine, NicVAX, and its effects on smoking behavior," investigators in the United States report.
According to D.K. Hatsukami and colleagues at the University of Minnesota, "Smokers (N=68) were recruited for a noncessation treatment study and assigned to 1 of 3 doses of the nicotine vaccine (50, 100, or 200 mcg) or placebo. They were injected on days 0, 28, 56, and 182 and monitored for a period of 38...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly